Last week Clovis filed Rubraca (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC), and AZ and MSD have followed this with their Lynparza (olaparib). AZ is targeting the ...

Part of the issue is that NICE has ruled Lynparza does not qualify as an end-of-life therapy – even though AZ said “real-world” data showed life expectancy in this patient population is less ...

“We wish to inform you that the company has now received permission for voluntary withdrawal of Olaparib (Lynparza) 100mg and 150 mg tablets from the CDSCO (Central Drugs Standard Control ...